Daniel Collins

Of the 23 analysts covering Bristol-Myers Squibb (BMY) in August 2017, six analysts recommended a “strong buy,” and four analysts recommended a “buy.” Ten analysts recommended a “hold,” and three analysts recommended a “sell.”

In 4Q17, Novartis’s (NVS) Cosentyx generated revenues of $615 million compared to $391 million in 4Q16, which reflected ~57% growth on a year-over-year (or YoY) basis and ~11% growth quarter-over-quarter.

In February 2018, the US FDA approved Gilead Sciences’ Biktarvy for the treatment of individuals with HIV-1 infection.

Of the 19 analysts tracking Merck (MRK) stock in September, four recommended a “strong buy” while ten analysts recommended a “buy.”

On October 18, Johnson & Johnson announced a fourth-quarter cash dividend of $0.90 per share for its common stock.

Teva Pharmaceutical’s net income and diluted EPS in the first nine months of 2018 amounted to $541.0 million and $0.53, respectively.

In 1H17, Valeant Pharmaceuticals International’s (VRX) U.S. Diversified Products franchise reported revenues of $519.0 million compared to $848.0 million in 1H17.

Of the 22 analysts covering Pfizer (PFE) in August 2017, one analyst recommended a “strong buy” and ten analysts recommended a “buy.” On August 26, Pfizer had a consensus 12-month target price of $37.45 for a 12.7% return on investment.

In 4Q17, Eli Lilly’s (LLY) Taltz generated revenues of $172.5 million compared to $61.3 million in 4Q16.

Johnson & Johnson’s (JNJ) Surgery segment reported revenues of $2.4 billion in the third quarter compared to $2.3 billion in the third quarter of 2017.

In June, the FDA approved Avastin in combination with chemotherapy followed by Avastin monotherapy.

Of the eight analysts tracking Array BioPharma in June, three recommended a “strong buy,” while five recommended a “buy.”

Merck & Co.’s (MRK) Keytruda generated revenues of $1.9 billion in the third quarter, reflecting an ~80% YoY growth.

In 3Q17, Pfizer (PFE) generated revenues of $13.2 billion, an increase of ~1% on a year-over-year (or YoY) basis and a 1% increase on a quarter-over-quarter basis.

Celgene (CELG) has a focused and robust clinical pipeline that may help it launch new drugs in the future.

In Q1 2018, Roche Holding (RHHBY) reported revenues of ~13.6 billion Swiss francs compared to ~12.9 billion Swiss francs in Q1 2017.

In Q1 2018, Zimmer Biomet’s (ZBH) revenue grew ~2.3% YoY (year-over-year) to $2.0 billion.

In 2016, Biogen (BIIB) reported revenues of $11.4 billion, which reflected a ~6% year-over-year (or YoY) growth.

Tysabri revenue trends In 3Q17, Biogen’s (BIIB) Tysabri generated revenue of ~$469 million, which reflected a ~9% fall YoY (year-over-year) and a ~5% fall QoQ (quarter-over-quarter). In 3Q17, Tysabri generated US revenue of ~$267 million, which reflected an ~11% fall YoY and an ~8% fall QoQ. In 3Q17, outside the US market, Tysabri reported revenue of ~$203 […]

In the first quarter, Roche’s (RHHBY) Hemlibra generated revenues of 23 million Swiss francs.

In 2016, BioMarin Pharmaceuticals (BMRN) reported revenues of around $1.1 billion, a ~25% increase year-over-year (or YoY).

23 analysts were tracking Bristol-Myers Squibb in November 2017. Six of them recommended a “strong buy” rating, while four recommended a “buy.”

Galmed Pharmaceuticals stock rose 151.3% on June 12. The stock closed at $17.59, which is a 387% increase from its 52-week low of $3.61 on February 14.

In the second quarter, BioMarin Pharmaceutical (BMRN) reported revenues of $372.8 million compared to $317.4 million in Q2 2017.

In 2016, Pfizer’s (PFE) Xalkori reported revenues of ~$561 million, which reflected a ~15% YoY (year-over-year) rise.

In 1Q18, Jazz Pharmaceuticals’ (JAZZ) Xyrem generated revenue of $316.8 million compared to $272 million in 1Q17.

Of the three analysts tracking Novartis in November 2017, one recommends a “strong buy,” while two recommend a “hold.”

In 2Q17, Merck’s (MRK) Gardasil/Gardasil 9 generated revenues of ~$469 million, which reflected ~19% growth year-over-year and ~12% growth quarter-over-quarter.

In 1Q18, Vertex Pharmaceuticals’ (VRTX) Orkambi revenue rose ~20% YoY (year-over-year) to $354 million from $295 million.

On July 11, Opko Health (OPK) stock closed at $6.01, which represents 126% growth from its 52-week low of $2.66 in March.

In 2Q17, Inlyta generated revenues of ~$88 million, which represents an ~19% decline on a YoY basis and ~4% growth on a quarter-over-quarter basis.

Medtronic’s (MDT) Cardiac & Vascular Group generated revenues of $2.9 billion in the second quarter of fiscal 2019 compared to $2.8 billion in the second quarter of fiscal 2018.

In 3Q17, Biogen (BIIB) generated revenue of ~$3.1 billion, which reflected ~4% growth year-over-year.

Opko Health’s (OPK) cost of revenues declined from $157.4 million in Q2 2017 to $150.1 million in Q2 2018.

In 4Q17, Pfizer (PFE) generated revenues of $168 million from the Xtandi alliance which reflected ~21% growth on a year-over-year basis.

In 3Q17, Johnson & Johnson’s (JNJ) Stelara generated revenues of $1.1 billion, which reflected ~38% growth on a YoY basis and 14% growth on a quarter-over-quarter basis.

In 2016, Merck’s (MRK) Emend reported revenues of around $549 million, which reflected 3% year-over-year growth.

Johnson & Johnson, which reported its third-quarter earnings results on October 16, generated net revenue of $20.3 billion in the quarter.

On January 25, CannTrust Holdings’ (CNTTF) stock price closed at $6.87, ~5.19% higher than its closing price of $6.53 on January 24 and ~11% higher than its closing price of $6.21 on January 18.

In January 2018, the FDA granted a BTD to Novartis’s (NVS) Promacta for use along with standard immunosuppressive therapy.

Valeant Pharmaceuticals (VRX) announced that it would change its name to Bausch Health Companies, which is expected to be effective in July.

In 2016, Celgene’s (CELG) Revlimid generated revenues of around $6.9 billion, which reflected a ~20% year-over-year (or YOY) growth.

In 2016, AbbVie’s (ABBV) drug Humira reported revenue of ~$16.0 billion, which reflected a ~15% year-over-year (or YoY) rise.

On January 25, on the OTC markets, Auxly Cannabis Group’s stock price closed at $0.72, which is ~6.75% higher than its close of $0.67 on January 24 and reflects ~8% growth YTD (year-to-date).

On April 2, 2018, CASI Pharmaceuticals (CASI) stock opened at $4.20. It grew ~68% over the week to close at $7.01 on April 6.

In 2Q17, Merck’s (MRK) Januvia generated revenues of around $948 million, which reflected an ~11% decline on a year-over-year basis and 13% growth on a quarter-over-quarter basis.

In 2016, Biogen’s (BIIB) interferon therapies, Avonex and Plegridy, together reported revenues of around $2.8 billion, which reflected a drop of ~6% on a year-over-year (or YoY) basis.

In March 2017, the US Food and Drug Administration (FDA) approved Sanofi’s (SNY) and Regeneron Pharmaceuticals’ (REGN) Dupixent (dupilumab) for the treatment of individuals with moderate-to-severe atopic dermatitis.

In the US market in 4Q17, Ibrance generated revenues of $777 million, which reflected ~27% growth on a YoY basis.

In January 2017, Pfizer (PFE) and Sangamo Therapeutics (SGMO) entered into a key collaboration agreement.

Today, Zosano Pharma is trading at a stock price of $4.38, which represents ~5.92% growth from its closing price of $4.14 yesterday.

In 2Q17, Merck’s (MRK) Zepatier generated revenues of ~$517 million compared to $112 million in 2Q16.

Celgene has entered a strategic collaboration with Acceleron for the development of luspatercept.

In December 2017, Kite, a Gilead Sciences (GILD) company, presented long-term follow-up data from its pivotal ZUMA-1 trial of Yescarta.

In 4Q17, Teva Pharmaceutical’s (TEVA) generic medicines segment reported revenues of $3.1 billion compared to $3.7 billion in 4Q16.

In 1H17, Remicade generated revenues of around $437 million, which is a 37% decline year-over-year.

In July 2017, the FDA accepted Bristol-Myers Squibb’s supplemental New Drug Application (or sNDA) for expanding the indication of Sprycel.

In 4Q17, Novo Nordisk’s (NVO) Saxendra generated revenues of 697 million Danish kroner, which reflected a ~38% YoY growth.

In 2Q17, Amgen’s (AMGN) Aranesp generated revenues of ~$535 million, which represented a 6% year-over-year rise.

Regeneron Pharmaceuticals (REGN) markets Eylea in the United States, and Bayer (BAYZF) commercializes the drug outside the US market.

In 1H17, Teva Pharmaceutical’s (TEVA) oncology business generated revenues of ~$550 million, or ~9% lower YoY (year-over-year).

In 4Q17, Merck’s (MRK) Cubicin reported revenues of $92 million, which was ~23% lower on a YoY (year-over-year) basis.

Today, Aptinyx (APTX) is trading at $5.26, which is a ~70.5% decline from yesterday’s closing price of $17.83.

In 4Q17, Celgene’s (CELG) Abraxane generated revenues of $251 million, which reflected a decline of ~6% on a YoY (year-over-year) basis.

In Q2 2018, Merck’s (MRK) Keytruda generated revenues of $1.67 billion compared to $881.0 million in Q2 2017, reflecting ~89% YoY growth.

In 4Q17, Amgen’s (AMGN) Repatha generated revenues of $98 million, which reflected a 69% growth YoY (year-over-year) and a 10% growth quarter-over-quarter.

In September 2018, Medtronic (MDT) announced that the company would acquire all outstanding shares of Mazor Robotics (MZOR) for $58.50 per American depository share.

In December 2017, Gilead Sciences (GILD) and its subsidiary specialized in cell therapy, Kite, entered into an agreement with Cell Design Labs.

Twenty-one analysts were tracking AbbVie in August 2017. Three analysts suggested a “strong buy,” while seven suggested a “buy.”

AbbVie’s (ABBV) Imbruvica generated revenue of $708 million in 4Q17 and $511 million in 4Q16, reflecting ~39% growth YoY (year-over-year) and ~3% growth quarter-over-quarter.

Bausch Health’s (BHC) net revenues declined from $4.3 billion in H1 2017 to $4.1 billion in H1 2018, reflecting an ~5.0% year-over-year decline.

In 2Q17, AbbVie’s (ABBV) Humira generated revenues of $4.7 billion, which was a 14.0% rise YoY (year-over-year) and a 15.0% rise QoQ (quarter-over-quarter).

Analysts estimate that in 1Q18, Exelixis will generate revenue of $141.0 million compared to $120.1 million in 4Q17.

In the second quarter, Alkermes (ALKS) reported revenues of $304.6 million—compared to $218.8 million in the second quarter of 2017.

In 4Q17, Valeant Pharmaceuticals (VRX) generated revenues of $2.2 billion compared to $2.4 billion in 4Q16.

In 1Q17, Merck (MRK) generated revenues of ~$9.4 billion, which reflected 1% YoY growth. Merck expects its GAAP net revenues in fiscal 2017 to reach $39.1 billion–$40.3 billion.

Amicus Therapeutics (FOLD) plans to start the pivotal trial for AT-GAA in the second half of 2018.

On November 26, Abiomed (ABMD) stock closed at $311.15, a ~3.92% rise from its previous day’s close of $299.41 on November 23.

In 2Q17, Celgene’s (CELG) Pomalyst generated revenues of ~$391 million, which reflected ~23% growth on a year-over-year basis.

Exelixis (EXEL) is scheduled to report its second-quarter earnings results on August 1.

In 2016, Pfizer’s (PFE) Prevnar 13 reported revenues of ~$5.7 billion, which reflected a ~8% decline on a YoY (year-over-year) basis.

In 1Q18, Exelixis (EXEL) generated revenues of $212.3 million, compared to $80.89 million in 1Q17. In 1Q18, Exelixis witnessed ~77% growth on a quarter-over-quarter basis.

On September 10, Intellia Therapeutics stock closed at $26.98, a ~0.95% fall from the previous day’s close of $27.24.

In 4Q17, Risperdal Consta generated revenues of $197.0 million, which is an ~6.2% decline on a YoY basis.

In 2016, Pfizer’s (PFE) Medrol reported revenues of ~$450 million, which represented a ~12% rise on a YoY (year-over-year) basis.

Twenty-six analysts are tracking Amgen in January 2018. Four analysts recommended a “strong buy” while seven analysts recommended a “buy.”

In June, Johnson & Johnson (JNJ) accepted a binding offer from Platinum Equity to acquire its LifeScan business for ~$2.1 billion.

In 3Q17, Bristol-Myers Squibb’s (BMY) Sprycel generated revenues of $509 million, an 8% increase on a year-over-year (or YoY) basis and ~1% growth on a quarter-over-quarter basis.

In the second quarter, Spectrum Pharmaceuticals (SPPI) generated net revenues of $24.2 million compared to $34.3 million in Q2 2017.

ContraVir Pharmaceuticals is focused on the development of antiviral therapies with a special focus on the development of anti-HBV therapies.

Merck & Company’s (MRK) Januvia reported revenue of $880 million in Q1 2018 compared to $839 million in Q1 2017.

Jazz Pharmaceuticals reported revenues of $500.5 million in Q2 2018 compared to $394.4 million in Q2 2017, a ~27% YoY increase and a ~13% sequential increase.

Of the 24 analysts covering Amgen, four have recommended a “strong buy” for the stock, while six have recommended a “buy.”

In the first nine months of this year, Pfizer’s (PFE) Ibrance revenue grew 24% YoY (year-over-year) to $3.0 billion from $2.4 billion.

GW Pharmaceuticals’ (GWPH) net income was -$295.2 million in fiscal 2018—compared to -$170.5 million in fiscal 2017.

On January 28, Cara Therapeutics’ (CARA) stock price closed at $14.82, which is an ~4.02% discount compared to its previous close.

Today, on the OTC markets, iAnthus Capital Holdings stock (ITHUF) is trading ~3.63% above yesterday’s closing price of $4.84.

On January 25, Charlotte’s Web Holdings’ (CWBHF) stock price closed at $14.41, ~4.87% higher than its closing price of $13.74 on January 24 and ~11% higher than its closing price of $6.21 on January 18.

On January 25, Innovative Industrial Properties (IIPR) stock price closed at $59.94, ~3.52% higher than its closing price of $57.90 on January 24 and ~10% higher compared than its closing price of $54.32 on January 18.

Today, Zimmer Biomet Holdings’ (ZBH) ROSA Knee System received FDA 510(k) clearance for robotically assisted total knee replacement surgeries.